Accurate diagnostic testing plays a critical role in the management of breast cancer, particularly the molecular profiling of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). This evidence concerns the gene PGR and breast carcinoma.